Spero Therapeutics (SPRO) Total Non-Current Liabilities (2016 - 2022)

Spero Therapeutics (SPRO) has 7 years of Total Non-Current Liabilities data on file, last reported at $48.9 million in Q4 2022.

• For the quarter ending Q4 2022, Total Non-Current Liabilities fell 40.39% year-over-year to $48.9 million; the trailing twelve-month figure through Dec 2022 stood at $48.9 million (down 40.39% YoY), and the FY2022 full-year result was $48.9 million, down 40.39% from the prior year.
• Total Non-Current Liabilities for Q4 2022 stood at $48.9 million, up from $31.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $83.4 million in Q1 2022 and bottomed at $5.9 million in Q1 2018.
• The 5-year median for Total Non-Current Liabilities is $19.3 million (2019), against an average of $29.2 million.
• The widest annual swing landed in 2018, when Total Non-Current Liabilities surged 3450.5%; it then tumbled 40.39% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $12.9 million in 2018, then surged by 49.1% to $19.3 million in 2019, then jumped by 41.46% to $27.3 million in 2020, then surged by 200.66% to $82.0 million in 2021, then sank by 40.39% to $48.9 million in 2022.
• The last three Total Non-Current Liabilities figures came in at $48.9 million (Q4 2022), $31.9 million (Q3 2022), and $27.6 million (Q2 2022), per Business Quant data.

Peer Comparison